FDA approves Targiniq ER with abuse-deterrent properties
[7/23/2014] FDA has approved Targiniq ER, a new extended-release pain reliever that contains a combination of oxycodone and naloxone. Targiniq ER is the second extended-release/long-acting (ER/LA) opioid analgesic with FDA-approved labeling describing the product’s properties that are expected to reduce, but not totally prevent, abuse by snorting or injecting.
July 23, 2014
- FDA approves new extended-release oxycodone with abuse-deterrent properties
FDA News Release
- A reminder of the promise and limitations of abuse-deterrent properties
FDA Voice Blog
- Targiniq ER Drug Details